| __timestamp | Travere Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 570979 | 3243000 |
| Thursday, January 1, 2015 | 2185000 | 2472000 |
| Friday, January 1, 2016 | 4554000 | 2548000 |
| Sunday, January 1, 2017 | 3605000 | 19623000 |
| Monday, January 1, 2018 | 5527000 | 30421000 |
| Tuesday, January 1, 2019 | 5234000 | 32793999 |
| Wednesday, January 1, 2020 | 6126000 | 28304000 |
| Friday, January 1, 2021 | 6784000 | 620000 |
| Saturday, January 1, 2022 | 7592000 | 755000 |
| Sunday, January 1, 2023 | 11450000 | 1322000 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. Travere Therapeutics, Inc. and Viridian Therapeutics, Inc. offer a fascinating glimpse into this dynamic. Over the past decade, Travere's cost of revenue has seen a steady increase, peaking in 2023 with a 100% rise from 2014. In contrast, Viridian's expenses fluctuated significantly, with a dramatic spike in 2019, reaching nearly 10 times their 2014 costs. This volatility highlights the challenges and opportunities within the biotech sector. Notably, both companies experienced a dip in costs in 2021, possibly reflecting strategic shifts or market conditions. As we delve into these insights, it becomes evident that managing costs effectively is pivotal for sustaining growth and innovation in the biotech industry.
Pfizer Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Pfizer Inc. and Viridian Therapeutics, Inc.
Amgen Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sanofi and Travere Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Viatris Inc. vs Travere Therapeutics, Inc.
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Analyzing Cost of Revenue: Evotec SE and Viridian Therapeutics, Inc.